LFCR

#3704
Lifecore Biomedical, Inc. - Common Stock
4.5 5 USD
0.00%
Market Price
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
4.55
4.55
Year Range
3.63
8.98
Daily Change
+0.22%
Monthly Change
+4.12%
6 month change
-38.35%
Year Change
-40.68%
Previous Close
4.5 4
Open
4.5 5
Low
4.5 5
High
4.5 5
Volume
21
Open full chart

Financials

Overview Statement Statistics Documents

2026

Current report, Q3 FY2026
LIFECORE BIOMEDICAL, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
LIFECORE BIOMEDICAL, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
LIFECORE BIOMEDICAL, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
LIFECORE BIOMEDICAL, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
LIFECORE BIOMEDICAL, INC. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
LIFECORE BIOMEDICAL, INC. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
LIFECORE BIOMEDICAL, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
LIFECORE BIOMEDICAL, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
LIFECORE BIOMEDICAL, INC. current report, Q1 FY2026
8-K

2025

Current report, Q4 FY2025
LIFECORE BIOMEDICAL, INC. current report, Q4 FY2025
8-K

LIFECORE BIOMEDICAL, INC. current report, Q1 FY2008

Full document

Business Context and Reporting Period

This Form 8-K is a current report filed by Landec Corporation (not Lifecore Biomedical, Inc., as indicated in the metadata) on January 2, 2008. The filing addresses a change in the company's independent registered public accounting firm.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on corporate governance regarding the audit firm.

Material Changes

  • Dismissal of Previous Auditor: On January 2, 2008, the Audit Committee dismissed Ernst & Young LLP (E&Y) as the independent registered public accounting firm.
  • Appointment of New Auditor: On the same date, the company appointed McGladrey & Pullen, LLP (M&P) as the new independent registered public accounting firm.
  • Scope of New Engagement: M&P is engaged to audit the fiscal year ending May 25, 2008, and to perform procedures for quarterly reports beginning with the quarter ending February 24, 2008.

Management Commentary and Risks

  • Audit Opinions: E&Y's reports for the fiscal years ended May 27, 2007, and May 28, 2006, did not contain adverse opinions, disclaimers, or qualifications regarding uncertainty, audit scope, or accounting principles.
  • Disagreements: The company reported no disagreements with E&Y on accounting principles, financial statement disclosure, or auditing scope during the two most recent fiscal years or the interim period through January 2, 2008.
  • Reportable Events: There were no "reportable events" as defined in Item 304(a)(1)(v) of Regulation S-K during the relevant periods.
  • Consultation with New Auditor: The company had not consulted with M&P regarding accounting principles or potential audit opinions prior to their engagement.

Investor Verification Checklist

  • Verify the reasons for the dismissal of Ernst & Young LLP, as the filing states no disagreements occurred but does not explicitly state the strategic rationale.
  • Review the letter from Ernst & Young LLP (Exhibit 10.74) to confirm their agreement with the company's statements regarding the dismissal.
  • Monitor the upcoming quarterly report (Form 10-Q) for the quarter ending February 24, 2008, to assess the transition to the new auditor.
  • Confirm the company name discrepancy between the metadata (Lifecore Biomedical) and the filing (Landec Corporation).

News